Hikma Pharmaceuticals Share Discussion Threads

[robertball] 06/11/2018 20:31

It's Thursday for trading stmt

[eentweedrie] 06/11/2018 10:35

tomorrow in fact

[robertball] 06/11/2018 09:37

Results soon

[robertball] 01/11/2018 08:12

Trading update next week

[robertball] 01/10/2018 07:51

After a pause.....

[bantam175] 17/9/2018 09:22

Barclays reiterate their 1400 guidance today. What are they on?

[robertball] 06/9/2018 15:08

Has Pfizer sorted their problems out?

[gerrym two] 21/8/2018 12:11

Traded no trades

[gerrym two] 21/8/2018 12:10

We said HIk would be back at 20 soon...it could get there today !! Will keep going in my view and on the back of a weak or at least a flat market.....what price does it have to get to get back into FT 100... or maybe it is ??I bought again at 1860p ...trades get the whole way up, my best trades share this year...by a distance.

[suetballs] 20/8/2018 08:54

Back into profit with hik and I think there is more to come.
Happy days.
Suet

[r ball] 15/8/2018 12:55

no. who from?

[bantam175] 15/8/2018 12:38

What odds on a possible bid before the share price gets to high I wonder?

[r ball] 15/8/2018 11:38

so good results on the back of Pfizer issues.

[bantam175] 15/8/2018 08:52

Brokers too embarrassed to put heads above water atm. Especially Barclays with their underweight 1100 target just 5 days ago.


Return to ftse100 could see these at £25 and higher still if the FDA approval goes through next year.


All imho dyor etc

[pre] 15/8/2018 07:49

results exceeded expectations...50k buy just went through...upgrades from brokers?

[broadwood] 15/8/2018 07:30

Generic drugmaker Hikma Pharmaceuticals issued its interim results for the six months ended 30 June on Wednesday, reporting an 11% improvement in group revenue to $989m, or 10% in constant currency.
The FTSE 250 company said its operating profit for the period was $174m, up 54%, while core group operating profit rose 22% to $214m, or 23% in constant currency.

Core basic earnings per share totalled 61.4 US cents, up 35%, and 38% in constant currency, with basic earnings per share rising 53% to 44.0 cents, or 57% in constant currency.
Cash flow from operations reached $185m.
Hikma said its net debt fell to $501m, from $546m at the end of December, with “healthy”; leverage ratios maintained.
Its board declared an interim dividend of 12 cents per share, up from 11 cents per share a year ago.
The company also raised its guidance for the injectables and generics businesses, and reiterated it for the branded business.
“I am pleased with our first half performance, with each of our three business segments achieving revenue and, importantly, profit growth,” said Hikma chief executive officer Siggi Olafsson.
“Our injectables business continues to demonstrate resilience.
“Our broad portfolio, extensive manufacturing capabilities and geographic footprint are enabling us to respond quickly to changing market dynamics and grow our market share.”
Olafsson said that in the generics business, Hikma was “successfully” driving demand for its “more differentiated”; in-market products, and was making progress reducing its cost base.
“We achieved good results in the branded business, taking into consideration the usual seasonality.
“In the first half, we renewed our focus on advancing our pipnlinee, enhancing our corporate research and development team and accelerating new projects.
“More broadly, we are strengthening key functions across the group and bringing new capabilities to ensure we have the right teams in place to take the business forward.”
Hikma’s performance in the first half exceeded the board’s expectations, Olafsson said, and it was reportedly “pleased”; to be able to raise its guidance for both the injectables and generics businesses for the full year.
“The measures we have taken and investments we have made across the group over the past year are delivering results, but we still have work to do.
“Our markets are competitive and we don't expect the same demand for some of our injectable products to continue into 2019,” Siggi Olafsson explained.
“This means we must remain focused on strengthening our customer relationships, improving profitability and advancing our pipeline to ensure future growth.”

[eentweedrie] 15/8/2018 07:14

congratulations!

[karateboy] 15/8/2018 07:11

So I was right to say last night that results will prove Numis was wrong to advice its investors to sell.

[eentweedrie] 15/8/2018 07:04

auction is taking a while

[karateboy] 15/8/2018 07:01

Interim is increased from 11 cents to 12 cents.

[broadwood] 15/8/2018 06:38

Our performance in the first half exceeded our expectations and we are pleased to be able to raise our guidance for both our Injectables and Generics businesses for the full year.

[bantam175] 15/8/2018 06:17

Results far and away better than expected.

Been accumulating (selling peaks buying troughs) for a while. Holding tight now for the time being.

£20ps a likely possibility imo.

imho, dyor etc etc

[richtea2517] 15/8/2018 06:06

Wish I'd bought more when under a tenner. Hindsight...

[karateboy] 14/8/2018 21:58

Should prove how wrong was Numis.